Table 2. Clinical demographic data of BAV and DCM patients.
| Characteristics | Patients with BAV & calcification | Patients with DCM | P value |
|---|---|---|---|
| Patients (n) | 22 | 17 | |
| Age (y) | 50.55 | 44.53 | |
| Gender, Male (%) | 15 (68.2%) | 12 (70.6%) | 0.872 |
| Risk Factors | |||
| Hypertension | 5 (22.7%) | 2 (11.8%) | 0.376 |
| Hyperlipidaemia | 4 (18.2%) | 3 (17.6%) | 0.966 |
| Diabetes mellites | 1 (4.5%) | 0 (0%) | 0.373 |
| Valvular dysfunction (aortic/mitral) | 22 (100%) | 6 (35.3%) | 0 |
| Hyperinflammatory responses (CRP/PCT) | 4 (18.2%) | 4 (23.5%) | 0.682 |
| ECG parameters | |||
| LVEF (%) | 61.1 ± 1.58 | 28.2 ± 2.4 | <0.0001 |
| Transvalvular gradient (mmHg) | 62.5 ± 30.4 | 0 | <0.0001 |
| Diameter of annulus (cm) | 2.6 ± 0.4 | 2.0 ± 0.6 | 0.0006 |
| Diameter of ascending aorta (cm) | 4.6 ± 0.5 | 2.9 ± 0.4 | <0.0001 |
| Diameter of aortic sinus (cm) | 4.2 ± 0.5 | 2.7 ± 0.6 | <0.0001 |
| Transvalvular velocity (m/s) | 3.8 ± 1.0 | 1.4 ± 0.4 | <0.0001 |
| Medications | |||
| Statins | 2 (9.1%) | 1 (5.9%) | 0.709 |
| ACEI/ARB | 3 (13.6%) | 3 (17.6%) | 0.731 |
| β-blockers | 5 (22.7%) | 4 (23.5%) | 0.953 |
Notes.
Data were shown as mean ± SD.
- BAV
- Bicuspid Aortic Valve
- DCM
- Dilated Cardiomyopathy
- CRP
- C-reactive protein
- PCT
- Procalcitonin
- LVEF
- Left Ventricular Ejection Fraction
- ACEI
- Angiotensin Converting Enzyme Inhibitor
- ARB
- Angiotensin Receptor Blocker